Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Failed axon connections homolog, metaxin-like GST domain containing (FAXC) is a conserved protein coding gene implicated in human cancer, particularly cholangiocarcinoma. Functionally, FAXC acts as a scaffold protein in mitochondria, forming a complex with annexin A2 (ANXA2) and c-SRC to enhance phosphorylation of ANXA2, thereby promoting epithelial–mesenchymal transition and hypoxia-driven signaling—processes crucial for tumorigenesis. The FAXC gene's role in mammals is still being defined; its Drosophila homolog coordinates axon bundle formation and maintenance, suggesting a broader influence on cytoskeletal and signaling pathways. FAXC is considered a candidate therapeutic target in oncology, though it lacks direct drug modulators or validated biomarkers. Clinical translation should proceed cautiously due to limited characterization of its normal physiological roles[1][2][3][4][5].
If targeted, would likely act via disruption of kinase complex formation (e.g., inhibition of FAXC/ANXA2/c-SRC complex assembly or ANXA2 phosphorylation cascade)[1]; Potential for indirect modulation of EMT and hypoxia pathways[1]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Failed axon connections homolog, metaxin-like GST domain containing (FAXC).